AULSF:OTC-AULSF (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 0.005

Change

0.00 (0.00)%

Market Cap

USD 17.01B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Austar Lifesciences Limited, an investment holding company, engages in the provision of integrated engineering solutions to pharmaceutical manufacturers and research institutes in Mainland China and internationally. The company operates through Liquid and Bioprocess System; Clean Room and Automation Control and Monitoring System; Powder and Solid System; GMP Compliance Service; Life Science Consumables; and Distribution and Agency of Pharmaceutical Equipment segments. It also offers clean utility and bioprocess equipment, clean room, automation control and monitor system; bioprocess equipment consumables, and laboratory solutions. In addition, the company provides pharmaceutical process contamination control; packaging and aseptic containment; biosafety lab animal equipment, and consumables, as well as offers powder and solid equipment; freeze-dryer, sterile filling and visual inspection equipment. Further, it offers project management and process engineering; engineering design and consulting services; operation and maintenance of facility management systems. Additionally, the company provides lifecycle digital solutions and professional consulting services. Austar Lifesciences Limited was founded in 1991 and is headquartered in Shanghai, China.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-10 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
SEMHF Siemens Healthineers AG

N/A

USD 67.08B
SMMNY Siemens Healthineers AG ADR

+0.59 (+2.04%)

USD 66.51B
RYLPF Koninklijke Philips N.V

N/A

USD 25.99B
SONVF Sonova Holding AG

+2.41 (+0.72%)

USD 20.26B
OCPNF Olympus Corporation

N/A

USD 17.48B
SNNUF Smith & Nephew plc

N/A

USD 11.22B
WILLF Demant A/S

N/A

USD 9.04B
GNGBF Getinge AB

N/A

USD 5.34B
AMBBY Ambu A/S

N/A

USD 4.96B
GGNDF GN Store Nord A/S

N/A

USD 3.08B

ETFs Containing AULSF

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 17.01B 95% A 94% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector